RU2020103424A - Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения - Google Patents
Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения Download PDFInfo
- Publication number
- RU2020103424A RU2020103424A RU2020103424A RU2020103424A RU2020103424A RU 2020103424 A RU2020103424 A RU 2020103424A RU 2020103424 A RU2020103424 A RU 2020103424A RU 2020103424 A RU2020103424 A RU 2020103424A RU 2020103424 A RU2020103424 A RU 2020103424A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- paragraphs
- fusion protein
- seq
- per year
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762526377P | 2017-06-29 | 2017-06-29 | |
| US62/526377 | 2017-06-29 | ||
| PCT/EP2018/067523 WO2019002532A1 (en) | 2017-06-29 | 2018-06-29 | 21-DAY FUSION PROTEIN DRAFTING COMPRISING IX FACTOR AND HUMAN ALBUMIN FOR THE PROPHYLACTIC TREATMENT OF HEMOPHILIA AND ASSOCIATED METHODS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2020103424A true RU2020103424A (ru) | 2021-07-29 |
| RU2020103424A3 RU2020103424A3 (enExample) | 2021-11-12 |
Family
ID=62815032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020103424A RU2020103424A (ru) | 2017-06-29 | 2018-06-29 | Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200115436A1 (enExample) |
| EP (1) | EP3645034B1 (enExample) |
| JP (1) | JP2020525498A (enExample) |
| KR (1) | KR102597725B1 (enExample) |
| CN (1) | CN110799209A (enExample) |
| AU (1) | AU2018294517B2 (enExample) |
| CA (1) | CA3068360A1 (enExample) |
| DK (1) | DK3645034T5 (enExample) |
| ES (1) | ES2963665T3 (enExample) |
| IL (1) | IL271160B2 (enExample) |
| MX (1) | MX2019014651A (enExample) |
| PL (1) | PL3645034T3 (enExample) |
| RU (1) | RU2020103424A (enExample) |
| SG (1) | SG10202111032PA (enExample) |
| WO (1) | WO2019002532A1 (enExample) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2275557A1 (en) | 2000-04-12 | 2011-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| AU2010284977A1 (en) * | 2009-08-20 | 2012-03-29 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| NZ605348A (en) * | 2010-07-09 | 2015-01-30 | Biogen Idec Hemophilia Inc | Factor ix polypeptides and methods of use thereof |
| TWI810729B (zh) * | 2012-09-25 | 2023-08-01 | 美商百歐維拉提夫治療公司 | Fix多肽的應用 |
| JP2017502036A (ja) * | 2013-12-23 | 2017-01-19 | シーエスエル、リミテッド | 血友病の予防的処置のための第ix因子を含む融合タンパク質およびその方法 |
| WO2015154139A1 (en) * | 2014-04-11 | 2015-10-15 | Csl Limited | Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor |
-
2018
- 2018-06-29 IL IL271160A patent/IL271160B2/en unknown
- 2018-06-29 RU RU2020103424A patent/RU2020103424A/ru unknown
- 2018-06-29 MX MX2019014651A patent/MX2019014651A/es unknown
- 2018-06-29 CA CA3068360A patent/CA3068360A1/en active Pending
- 2018-06-29 US US16/626,153 patent/US20200115436A1/en not_active Abandoned
- 2018-06-29 ES ES18736860T patent/ES2963665T3/es active Active
- 2018-06-29 KR KR1020207002673A patent/KR102597725B1/ko active Active
- 2018-06-29 DK DK18736860.0T patent/DK3645034T5/da active
- 2018-06-29 EP EP18736860.0A patent/EP3645034B1/en active Active
- 2018-06-29 CN CN201880042643.9A patent/CN110799209A/zh active Pending
- 2018-06-29 WO PCT/EP2018/067523 patent/WO2019002532A1/en not_active Ceased
- 2018-06-29 AU AU2018294517A patent/AU2018294517B2/en active Active
- 2018-06-29 SG SG10202111032PA patent/SG10202111032PA/en unknown
- 2018-06-29 PL PL18736860.0T patent/PL3645034T3/pl unknown
- 2018-06-29 JP JP2019572377A patent/JP2020525498A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL271160B1 (en) | 2025-01-01 |
| PL3645034T3 (pl) | 2024-09-02 |
| AU2018294517B2 (en) | 2024-09-26 |
| KR20200019749A (ko) | 2020-02-24 |
| AU2018294517A1 (en) | 2020-01-30 |
| WO2019002532A1 (en) | 2019-01-03 |
| MX2019014651A (es) | 2020-02-07 |
| ES2963665T3 (es) | 2024-04-01 |
| CA3068360A1 (en) | 2019-01-03 |
| US20200115436A1 (en) | 2020-04-16 |
| KR102597725B1 (ko) | 2023-11-06 |
| IL271160A (en) | 2020-01-30 |
| DK3645034T5 (da) | 2024-08-26 |
| DK3645034T3 (da) | 2023-11-20 |
| RU2020103424A3 (enExample) | 2021-11-12 |
| JP2020525498A (ja) | 2020-08-27 |
| IL271160B2 (en) | 2025-05-01 |
| SG10202111032PA (en) | 2021-11-29 |
| EP3645034B1 (en) | 2023-08-30 |
| EP3645034A1 (en) | 2020-05-06 |
| CN110799209A (zh) | 2020-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pusateri et al. | Dried plasma: state of the science and recent developments | |
| US20210238307A1 (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| Johnson et al. | Clinical investigation of intermediate‐and high‐purity antihaemophilic factor (factor VIII) concentrates | |
| Courter et al. | Clinical evaluation of B-domain deleted recombinant factor VIII in previously treated patients | |
| RU2003127018A (ru) | Комбинированное применение полипептидов фактора vii и полипептидов фактора viii | |
| EA032336B1 (ru) | Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции | |
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| RU2016129911A (ru) | Слитые белки, содержащие фактор ix, для профилактического лечения больных гемофилией и способы его осуществления | |
| Morfini et al. | Prevalence of infection with the hepatitis C virus among Italian hemophiliacs before and after the introduction of virally inactivated clotting factor concentrates: a retrospective evaluation | |
| Rodriguez et al. | Advances in hemophilia: experimental aspects and therapy | |
| Cuker et al. | Efficacy and safety of fidanacogene elaparvovec in adults with moderately severe or severe hemophilia B: results from the phase 3 BENEGENE-2 gene therapy trial | |
| Alfaleh et al. | David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors | |
| KR20250024800A (ko) | A형 및 b형 혈우병의 치료를 위한 피투시란 | |
| RU2020103424A (ru) | Схема введения с 21-дневными интервалами слитых белков, содержащих фактор ix и альбумин человека, для профилактического лечения гемофилии и способы такого лечения | |
| AU2015229222B2 (en) | Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders | |
| Hogan et al. | α1-Antitrypsin: key player or bystander in acute respiratory distress syndrome? | |
| US11554156B2 (en) | Pharmaceutical formulations of C1 esterase inhibitor | |
| CN101848727A (zh) | 脱铁乳铁蛋白组合物及其用于治疗病毒性丙型肝炎的方法 | |
| CN102065844A (zh) | 干燥转谷氨酰胺酶组合物 | |
| Spira et al. | Safety and efficacy of a long-acting liposomal formulation of plasma-derived factor VIII in haemophilia A patients. | |
| JP2020525498A5 (enExample) | ||
| JP2019524089A5 (enExample) | ||
| RU2004117534A (ru) | Фармацевтическая композиция, содержащая полипептиды фактора vii и полипептиды фактора v | |
| JPS59181223A (ja) | インタ−フエロンの安定化法 | |
| Escobar | Treatment on demand–in vivo dose finding studies |